title: Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis.
abstract: Interferon (IFN)-β is a type I IFN commonly produced by the innate immune system in response to viral infection. IFN-β is also used for the treatment of patients with the relapsing-remitting form of multiple sclerosis (RRMS); however, IFN-β therapy is unable to confer a significant benefit for primary-progressive MS (PPMS) patients. In this study, we assessed the gene profiles of peripheral blood mononuclear cells (PBMCs) isolated from PPMS, RRMS, and healthy donors (HD) in response to IFN-β treatment in vitro to examine genetic mechanisms underlying the inadequate response of IFN-β therapy in PPMS patients. Here, we show that HLA-G was significantly less up-regulated in response to IFN-β in PBMCs from PPMS compared to those from RRMS. This data suggests HLA-G to be a possible candidate gene found impaired in IFN-β-mediated immune regulation in PPMS patients.
authors.affiliation: Department of Neurology, Rutgers-Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA.
authors.forename: Sridhar
authors.initials: S
authors.lastname: Boppana
authors.forename: John E
authors.initials: JE
authors.lastname: Mindur
authors.forename: Konstantin E
authors.initials: KE
authors.lastname: Balashov
authors.forename: Suhayl
authors.initials: S
authors.lastname: Dhib-Jalbut
authors.forename: Kouichi
authors.initials: K
authors.lastname: Ito
mesh_terms: D059951:HLA-G Antigens / Q000235:genetics / Q000378:metabolism; D006801:Humans; D016899:Interferon-beta / Q000235:genetics / Q000378:metabolism*; D053583:Interleukin-1beta / Q000494:pharmacology*; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000378:metabolism; D020528:Multiple Sclerosis, Chronic Progressive / Q000473:pathology*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000473:pathology*; D015854:Up-Regulation / Q000187:drug effects*
chemical_list: D059951:HLA-G Antigens; D053583:Interleukin-1beta; D016899:Interferon-beta
keywords: HLA-G PPMS; IFN beta inducible genes; IFN beta therapy; Multiple sclerosis; PPMS; RRMS